If you have been reading about CAS Registry Number and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-09-10. Where a claim depends on a specific study, the study is described rather than over-claimed.
Identity checks for dihexa usually rely on mass spectrometry and chromatographic purity analysis. A lyophilized powder is the common supplied form, and it may appear as a white to off-white solid. Aqueous solubility is limited, so laboratory work often uses an organic solvent such as dimethyl sulfoxide to prepare stock solutions. Because the peptide is not a standard pharmaceutical product, exact specifications can vary between suppliers. Certificates of analysis may accompany a batch, but they are not equivalent to regulatory approval.
Dihexa is a synthetic peptide whose structure is modeled on angiotensin IV. Its chemical name often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, though vendor and publication naming can differ. The molecule combines a short amino acid sequence with a hexanoic acid group and an amide terminus. It is classed as a small research peptide rather than a conventional drug. Databases may list it under several synonyms, so matching names are important when comparing sources.
The angiotensin IV connection places dihexa in a family of short peptides studied for effects on central nervous system signaling. Angiotensin IV itself is a metabolite of angiotensin II, and analogs have been explored in cardiovascular and neurological research. Dihexa differs from the natural peptide through structural modifications intended to alter stability and receptor interactions. Published descriptions sometimes call it a hepatocyte growth factor mimetic, although that label reflects proposed activity rather than a confirmed clinical mechanism.
Regulatory status differs by country, but dihexa is generally not approved as a therapeutic product. It is often sold as a research chemical, which means purity, labeling, and handling fall outside pharmaceutical drug standards. Some jurisdictions restrict the sale of peptides intended for human consumption. Researchers and suppliers may therefore face different legal requirements depending on location. Import rules and customs enforcement can also affect how such compounds move across borders.
Human safety data are sparse. No widely accepted dosing regimen, long-term safety profile, or clinical efficacy endpoint has been established. Published animal results can suggest directions for further study, but species differences and study design limit direct translation. Open questions include bioavailability, blood-brain barrier penetration, metabolism, and whether observed effects arise from a single target or multiple pathways. Replication across independent laboratories remains an important benchmark for evaluating the strength of preclinical claims.
Most published reports on dihexa come from cell cultures and animal models. Studies have examined markers of synapse formation, dendritic spine density, and performance on learning tasks in rodents. Proposed mechanisms center on hepatocyte growth factor and its c-Met receptor, with additional attention to angiotensin IV-related pathways. These findings are experimental and have not been confirmed as clinical benefits in humans. The literature often uses different tasks and endpoints, which complicates direct comparison across studies.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide analog | Modeled on angiotensin IV; not a natural hormone. |
| Common synonyms | Dihexa; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Naming conventions differ across vendors and papers. |
| CAS Registry Number | 1401708-83-6 | Listed in some chemical databases; verify against primary sources. |
| Appearance | White to off-white powder | Typical form for lyophilized research peptides. |
| Solubility | Soluble in DMSO; limited in water | Organic stock solutions are common in laboratory settings. |
In laboratory settings, dihexa is typically handled as a lyophilized peptide powder. Appropriate personal protective equipment and a ventilated workspace are standard practices for weighing and transferring research chemicals. Because the compound lacks regulatory approval for clinical use, it should not be given to people. Institutional safety rules and local regulations govern its acquisition, storage, and disposal. Suppliers often provide a certificate of analysis that lists purity, identity, and batch-specific handling notes.
Dissolution depends on the peptide’s salt form, purity, and the chosen solvent. Dimethyl sulfoxide is commonly used to prepare concentrated stock solutions, while aqueous buffers may show limited solubility. Sonication or gentle warming can sometimes aid dissolution, but excessive heat may promote degradation. Once in solution, the material is generally kept cold and protected from light. Researchers should verify solubility for each lot rather than assuming uniform behavior across suppliers.
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
Purity and identity are usually assessed with reverse-phase high-performance liquid chromatography (RP-HPLC) and mass spectrometry. RP-HPLC separates components by hydrophobicity and can estimate peptide purity. Mass spectrometry confirms molecular mass and helps detect truncations or modifications. Some laboratories also use amino acid analysis or nuclear magnetic resonance for structural verification. A certificate of analysis from a supplier may list these results, but independent verification is often recommended for critical work.
Regulatory status varies by country, and dihexa is not widely approved as a medicine. In many jurisdictions it is treated as a research chemical, which limits its legal sale, possession, and human use. Products marketed online may lack verified purity or identity, and labels can be inaccurate. Researchers typically source material from suppliers that provide analytical documentation and follow institutional safety rules. Open questions remain about long-term stability, metabolite formation, and human pharmacokinetics.
Dihexa is a synthetic peptide that has been examined in laboratory and animal research. Its design is based on angiotensin IV, a naturally occurring peptide fragment produced in the body. The short name dihexa appears in scientific papers and online discussions, while the full chemical name describes a modified peptide chain. It is not a vitamin, mineral, or plant-derived compound. Suppliers typically present it as a research chemical rather than an approved medicine.
The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.
Chemically, dihexa belongs to a broader group of angiotensin IV analogs. Researchers have modified the natural peptide to alter stability, binding, or distribution. Such changes can affect how the molecule behaves in experiments. The parent peptide angiotensin IV is involved in various physiological processes, but the modified analog is not identical to it. Public summaries sometimes blur the distinction between the natural fragment and the synthetic research compound. This distinction matters when interpreting study results.
== Career == After graduating from Ohio State University in 1938, Minnich wrote to Carl Moore to ask for a job and he offered her a position as a research technician helping start a Hematology department at Washington University. She remained at Washington University for her entire career. She was promoted to a research associate in 1954, research assistant professor in 1958, research associate professor in 1963, and full professor of Medicine in 1974 (the first person without a doctorate degree to reach this rank at Washington University). She became professor emeritus in 1978 and retired in 1984. She also worked at Barnes Hospital in St. Louis from 1975 to the mid-1980s as assistant and then associate director of Hematology. She was regarded as an excellent teacher and, in addition to her official teaching responsibilities, she gave informal "night courses" to pathologists, lab technicians, and others. She created a series of audiovisual teaching materials describing the morphology of blood and bone marrow that were published by the American Society of Clinical Pathologists in the early 1980s as a 10-part course in morphologic hematology.
=== Therapeutic opportunities === The ribosome is a prominent drug target for antibacterials, which interfere with translation at different stages of the elongation cycle Most clinically relevant translation compounds are inhibitors of bacterial translation, but inhibitors of eukaryotic translation may also hold therapeutic potential for application in cancer or antifungal chemotherapy. Elongation inhibitors show antitumor activity 'in vivo' and 'in vitro'. One toxic inhibitor of eukaryotic translation elongation is the glutarimide antibiotic cycloheximide (CHX), which has been co-crystallized with the eukaryotic 60S subunit and binds in the ribosomal E site. The structural characterization of the eukaryotic ribosome may enable the use of structure-based methods for the design of novel antibacterials, wherein differences between the eukaryotic and bacterial ribosomes can be exploited to improve the selectivity of drugs and therefore reduce adverse effects.
James Dell Talarico (né Collins; TAL-uh-REE-koh, born May 17, 1989) is an American politician, Presbyterian seminarian, and educator serving since 2018 as a member of the Texas House of Representatives. He is the Democratic Party's nominee in the 2026 U.S. Senate election in Texas. Born in Round Rock, Texas, Talarico graduated from the University of Texas at Austin with a Bachelor of Arts in government in 2011, and from Harvard University with a Master of Education degree in education policy in 2016. Before entering politics, Talarico was a middle school English teacher and an executive director for an education nonprofit. He is serving his fourth term in the Texas House of Representatives, having first been elected in 2018. While serving in the Texas House, Talarico started to pursue a Master of Divinity at Austin Presbyterian Theological Seminary. In 2025, he announced his candidacy for the United States Senate in 2026. He defeated U.S. representative Jasmine Crockett in the Democratic primary and will face the Republican nominee, Texas attorney general Ken Paxton, in the general election.
Robert H. Christenson, PhD, DABCC, FACB, is the current President of the American Association for Clinical Chemistry, AACC. As of 2026, he is a professor of pathology and professor of medical and research technology at the University of Maryland School of Medicine in Baltimore. He is a member of the editorial boards of Clinical Chemistry and the Journal of Clinical and Laboratory Analysis, and associate editor of Clinical Biochemistry.
Sources: en.wikipedia.org
Perchlorate was detected in Martian soil at the level of ~0.6% by weight. It was shown that at the Phoenix landing site it was present as a mixture of 60% Ca(ClO4)2 and 40% Mg(ClO4)2. These salts, formed from perchlorates, act as antifreeze and substantially lower the freezing point of water. Based on the temperature and pressure conditions on present-day Mars at the Phoenix lander site, conditions would allow a perchlorate salt solution to be stable in liquid form for a few hours each day during the summer. The possibility that the perchlorate was a contaminant brought from Earth was eliminated by several lines of evidence. The Phoenix retro-rockets used ultra pure hydrazine and launch propellants consisting of ammonium perchlorate or ammonium nitrate. Sensors on board Phoenix found no traces of ammonium nitrate, and thus the nitrate in the quantities present in all three soil samples is indigenous to the Martian soil. Perchlorate is widespread in Martian soils at concentrations between 0.5 and 1%. At such concentrations, perchlorate could be an important source of oxygen, but it could also become a critical chemical hazard to astronauts. In 2006, a mechanism was proposed for the formation of perchlorates that is particularly relevant to the discovery of perchlorate at the Phoenix lander site. It was shown that soils with high concentrations of chloride converted to perchlorate in the presence of titanium dioxide and sunlight/ultraviolet light. The conversion was reproduced in the lab using chloride-rich soils from Death Valley.
=== 4 November === The SAF claimed to have shot down a drone near Babanusa, while the RSF claimed to have shot down an Ilyushin warplane over the same city. The SAF acknowledged the loss of a cargo aircraft in the city along with its entire crew, but blamed the incident on a technical malfunction.
Acute Care Hospital Ambulatory Care Ambulatory Surgery Center Assisted Living Behavioral Health Clinical Laboratory Critical Access Hospital Dentistry DMEPOS Home Care (Private Duty) Home Health Home Infusion Therapy Hospice Office-Based Surgery Palliative Care PCAB (Compounding) Pharmacy Renal Dialysis Sleep The accreditation process for laboratories follows a two-year cycle, all other programs follow a three-year cycle. In early 2013, ACHC moved to headquarters in Cary, North Carolina. It welcomed its new CEO, José Domingos, and it launched its Behavioral Health Program.
Sources: en.wikipedia.org
== Pathway systems == The vast size of the Inca empire made it essential that efficient and effective transportation systems were created and built to assist in the exchanging of goods, services, people, etc. At one point, "their (the Inca) empire eventually extended across western South America from Quito in the north to Santiago in the south, making it the largest empire ever seen in the Americas and the largest in the world at that time (between c. 1400 and 1533 CE)." It is known to have "extended some 3500-4000 km along the mountainous backbone of South America." The trails, roads, and bridges were designed not only to link the empire physically, but these structures also helped the empire to maintain communication.
Nitazenes have fueled a drug crisis in the United Kingdom and Baltic States, with the British government reporting more than 400 overdose deaths from the drugs in the 18-month period through January 2025. In the UK, abuse of nitazene analogues first emerged in 2023 as an important cause of drug-overdose death, with it being linked to 54 deaths over a six-month period. Most of the deaths have occurred outside London. The source of supply is thought to be by post from laboratories in China, and some of the deaths have been associated by the mislabeling of nitazenes as fentanyl.
== Preparation == A frappé can be made with a cocktail shaker or, more commonly today, with an electric milk frother or milkshake machine. First, instant coffee (traditionally Nescafé), sugar (optional), and a little water are shaken or blended together until a thick foam is made. This is then poured into the serving glass with ice cubes and cold water. Milk (traditionally evaporated milk or sometimes condensed milk) is optionally added to it. The drink is almost always served with a drinking straw as the thick foam formed on top is considered unpleasantly bitter by many.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide analog related to angiotensin IV. It is studied in preclinical research for effects on neural signaling and synapse formation. It is not an approved medicine.
No. Dihexa shares a conceptual link to angiotensin IV but has different structural features. Those changes are intended to modify its behavior in biological systems.
It often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. Synonyms and CAS listings vary, so cross-checking identifiers is necessary.
Published human clinical trial data are limited or absent. Most available evidence comes from laboratory and animal studies. Human safety and efficacy remain unresolved.